Merck focuses on its top drugs for investors

Article Excerpt

We’re now seeing some attractive investment opportunities in drug stocks for our subscribers—and we’re adding the best of them to your Power Growth Investor. You could say this is related to the fight against COVID-19. But, it was going to happen anyway, due to regulatory and research developments that were already underway. COVID-19 simply gave it a boost. We do think the drug industry will enjoy great success in this coming decade. But, due to the nature of the business, results will vary widely and unpredictably from one drug company to another. Drug stocks suffer from high volatility and fierce competition. It still takes a long time and huge investment to develop a drug and win regulatory approval, which is not guaranteed. Even then, a proven drug can quickly lose market share if better alternatives appear. Still, there are promising stocks despite those challenges for drugmakers. Merck & Co. is one example. It stands out for investors with its Keytruda blockbuster drug, but…